Gland Pharma Limited (BOM:543245)

Gland Pharma Statistics

Total Valuation

Gland Pharma has a market cap or net worth of INR 381.08 billion. The enterprise value is 349.59 billion.

Market Cap	381.08B
Enterprise Value	349.59B

Important Dates

The last earnings date was Friday, May 15, 2026.

Earnings Date	May 15, 2026
Ex-Dividend Date	Aug 11, 2026

Share Statistics

Current Share Class	164.76M
Shares Outstanding	n/a
Shares Change (YoY)	+0.13%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	38.37%
Float	79.36M

Valuation Ratios

The trailing PE ratio is 37.09 and the forward PE ratio is 30.73.

PE Ratio	37.09
Forward PE	30.73
PS Ratio	5.93
PB Ratio	3.68
P/TBV Ratio	3.83
P/FCF Ratio	70.49
P/OCF Ratio	36.95
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.45, with an EV/FCF ratio of 64.66.

EV / Earnings	34.03
EV / Sales	5.44
EV / EBITDA	21.45
EV / EBIT	28.99
EV / FCF	64.66

Financial Position

The company has a current ratio of 4.68, with a Debt / Equity ratio of 0.03.

Current Ratio	4.68
Quick Ratio	3.31
Debt / Equity	0.03
Debt / EBITDA	0.17
Debt / FCF	0.52
Interest Coverage	36.24

Financial Efficiency

Return on equity (ROE) is 10.53% and return on invested capital (ROIC) is 12.20%.

Return on Equity (ROE)	10.53%
Return on Assets (ROA)	6.35%
Return on Invested Capital (ROIC)	12.20%
Return on Capital Employed (ROCE)	11.06%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	14.78M
Profits Per Employee	2.36M
Employee Count	4,351
Asset Turnover	0.54
Inventory Turnover	1.41

Taxes

In the past 12 months, Gland Pharma has paid 4.37 billion in taxes.

Income Tax	4.37B
Effective Tax Rate	29.86%

Stock Price Statistics

The stock price has increased by +51.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+51.70%
50-Day Moving Average	1,843.87
200-Day Moving Average	1,837.16
Relative Strength Index (RSI)	67.55
Average Volume (20 Days)	55,352

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gland Pharma had revenue of INR 64.31 billion and earned 10.27 billion in profits. Earnings per share was 62.28.

Revenue	64.31B
Gross Profit	39.85B
Operating Income	12.06B
Pretax Income	14.65B
Net Income	10.27B
EBITDA	16.30B
EBIT	12.06B
Earnings Per Share (EPS)	62.28

Balance Sheet

The company has 34.33 billion in cash and 2.84 billion in debt, with a net cash position of 31.49 billion.

Cash & Cash Equivalents	34.33B
Total Debt	2.84B
Net Cash	31.49B
Net Cash Per Share	n/a
Equity (Book Value)	103.58B
Book Value Per Share	628.81
Working Capital	59.18B

Cash Flow

In the last 12 months, operating cash flow was 10.31 billion and capital expenditures -4.91 billion, giving a free cash flow of 5.41 billion.

Operating Cash Flow	10.31B
Capital Expenditures	-4.91B
Depreciation & Amortization	4.24B
Net Borrowing	-880.62M
Free Cash Flow	5.41B
FCF Per Share	n/a

Margins

Gross margin is 61.97%, with operating and profit margins of 18.75% and 15.98%.

Gross Margin	61.97%
Operating Margin	18.75%
Pretax Margin	22.77%
Profit Margin	15.98%
EBITDA Margin	25.34%
EBIT Margin	18.75%
FCF Margin	8.41%

Dividends & Yields

This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.87%.

Dividend Per Share	20.00
Dividend Yield	0.87%
Dividend Growth (YoY)	11.11%
Years of Dividend Growth	n/a
Payout Ratio	28.87%
Buyback Yield	-0.13%
Shareholder Yield	0.74%
Earnings Yield	2.70%
FCF Yield	1.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	8